Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marshall Mazepa

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Blood|August 18, 2022
Sounding the alarm for prophylaxis in hTTPMarshall Mazepa
American Journal of Hematology|September 2, 2022
Caplacizumab for congenital thrombotic thrombocytopenic purpuraAaron Boothby, Marshall Mazepa
Arteriosclerosis, Thrombosis, and Vascular Biology|July 19, 2013
Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targetsMarshall Mazepa, Maureane Hoffman, Dougald Monroe
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Consequences of unmet pregnancy-specific health care needs in women with immune TTPJenna Brown, Clare Martin, Marshall Mazepa, et al.
Frontiers in Nephrology|August 28, 2024
Case report: Successful treatment of renal-limited thrombotic microangiopathy secondary to chronic lymphocytic leukemiaKristina Nasr, Sabine Karam, Marshall Mazepa, et al.
Journal of Hospital Medicine|June 26, 2020
A Fiery PivotR Cole Pueringer, Marshall Mazepa, Andrew Pj Olson, et al.
American Journal of Hematology|February 2, 2022
Transfusion-dependent anemia secondary to vitamin C deficiencyAllison M Angeli, Bryant Megna, Marshall Mazepa, et al.
American Journal of Therapeutics|January 3, 2018
Bortezomib for Refractory Immune-Mediated Thrombocytopenia PurpuraJoan D Beckman, Marian A Rollins-Raval, Jay S Raval, et al.
Blood|March 8, 2022
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpuraHridaya Shah, Ann Kim, Senthil Sukumar, et al.
Journal of Clinical Medicine|February 13, 2025
Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic PurpuraAaron B Boothby, Michael D Evans, Shangbin Yang, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Blood|August 18, 2022
Sounding the alarm for prophylaxis in hTTPMarshall Mazepa
American Journal of Hematology|September 2, 2022
Caplacizumab for congenital thrombotic thrombocytopenic purpuraAaron Boothby, Marshall Mazepa
Arteriosclerosis, Thrombosis, and Vascular Biology|July 19, 2013
Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targetsMarshall Mazepa, Maureane Hoffman, Dougald Monroe
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Consequences of unmet pregnancy-specific health care needs in women with immune TTPJenna Brown, Clare Martin, Marshall Mazepa, et al.
Frontiers in Nephrology|August 28, 2024
Case report: Successful treatment of renal-limited thrombotic microangiopathy secondary to chronic lymphocytic leukemiaKristina Nasr, Sabine Karam, Marshall Mazepa, et al.
Journal of Hospital Medicine|June 26, 2020
A Fiery PivotR Cole Pueringer, Marshall Mazepa, Andrew Pj Olson, et al.
American Journal of Hematology|February 2, 2022
Transfusion-dependent anemia secondary to vitamin C deficiencyAllison M Angeli, Bryant Megna, Marshall Mazepa, et al.
American Journal of Therapeutics|January 3, 2018
Bortezomib for Refractory Immune-Mediated Thrombocytopenia PurpuraJoan D Beckman, Marian A Rollins-Raval, Jay S Raval, et al.
Blood|March 8, 2022
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpuraHridaya Shah, Ann Kim, Senthil Sukumar, et al.
Journal of Clinical Medicine|February 13, 2025
Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic PurpuraAaron B Boothby, Michael D Evans, Shangbin Yang, et al.
Pageof 2